platieshop2013good.ru
Главная Ботокс керчь

При сахарном диабете надо часто есть

Врач машинцев николай николаевич.отзывы .клиника элорма .пластическая хирургия


Читать дальше

Как сделать что бы курить

Как убрать боли остеохондроза шейного отдела


Читать дальше

Если в подъезде кто-то курит рязань

Кривые изменения артериального давления при раздражении блуждающего нерва


Читать дальше

Презентация гормонорезистентного рака простаты


свечи от геморроя в форме свечи

1. Гарин A.M. Принципы и возможности современной эндокринной терапии опухолей. 2000:109-129.

2. Гарин A.M. Доцетаксел (Таксотер) в практике лечения злокачественных опухолей. 2003:88-94.

3. Давыдов М.И, Аксель Е.М. Злокачественные новообразования в России и странах СНГ в 2000г. 2002.

4. Дегтярь В.Г., Кушлинский Н.Е. Биотрансформация андрогенов в предстательной железе человека: ее значение в норме, причина или следствие нарушений метаболизма андрогенов при опухолях // Вестник ОНЦ РАМН. 1998. №2.

5. Матвеев Б.П., Бухаркин Б.В., Матвеев В.Б. Рак предстательной железы. 1999:143- 150.

6. Резников А.Г., Варга C.B. Антиандрогены. М. 1988.

7. Русаков И.Г., Алексеев Б.Я. Лечение гормонорезистентного рака 1 предстательной железы: роль эстрацита. Современная онкология 2004;т.63:116-121.

8. Харченко В.П., Гафанов P.A., Каприн А.Д., Костин A.A. Гормонорезистентный рак предстательной железы. Возможности лечения. Андрология и генитальная хирургия 2001;4:8-12.

9. Abrahamson Per-Anders. Revolutions in the management of hormone-refractory prostate cancer. European Urology Supplements 2 (2003) 1-2.

10. Benson R, Hartley-Asp B. Mechanisms of action and clinical uses of estramustine. Cancer Invest. 1990;8:375-380.

11. Bubley G, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999; 17:34613467.

12. Clarke GM, Cooke D. A basic course in statistics. // London: Edward Arnold -1978.

13. Cox DR. Some applications of exponential ordered scores. // Journal of the Royal Statistical Society 1964-№26-P. 103-110.

14. Cox DR. The analysis of exponentially distributed life-times with two types of failures. // Journal of the Royal Statistical Society 1959 - №21 - P.411-21.

15. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostate carcinoma. N Engl J Med. 1989; 321:419-424.

16. Crawford ED. Overview: hormone-refractory prostate cancer. Urology 1999;54(6A Suppl):l-7.

17. Dahllof B, Billstrom A, Cabrai F, Hartley-Asp B. Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res 53:4573-4581,1993.

18. Earhart RH. Docetaxel (Taxotere): preclinical and general clinical information. Semin Oncol. 1999;26:8-13.

19. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036-1042.

20. Eisenberger MA, Simon R, O'Dwyer PJ, et al. A réévaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol. 1985;3:827-841.

21. Fossa SD, Slee PH, Brausi M, et al. Flutamid versus prednisone in patients with prostate cancer simptomatically progressing after androgen-ablative therapy: a phase 3 study of the EORTC Genitourinary Group. J Clin Oncol 2001;19:62-71.

22. Garnick MB. Prostate cancer: screening, diagnosis, and management. Ann Intern Med.l993;l 18:804-818.

23. Haldar S, Basu A, and Croce C. Bcl-2 is the guardian of microtubule integrity. Cane Res 57: 229-233, 1997.

24. Harris KA, Reese DM. Treatment options in hormone-refractory prostate cancer: current and future approaches. Drugs 2001;61:2177-92.

25. Hudes G, Einhorn L, Ross E, et al. Vinblastine versus vinblastine plus oral estramustine" phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol. 1999;17:3160-3166.

26. Hudes G. Estramustine-based chemotherapy. Semin Urol Oncol. 1997;15:13-19.

27. Hudes GR, Greenberg R, Krigel RL, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol. 1992;10:1754-1761.

28. Hudes GR, Nathan F, Khater C. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1997; 15:3156.

29. Huggins C, Hodges CV: Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293-297, 1941.

30. Isaacs JT. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999; 26: 263 273.38.1versen P. Current topics in the treatment of hormone-refractory prostate cancer. European Urology Supplements 2 (2003) 3-8.

31. Joyce R, Fenton MA, Rode P, et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol. 1998;159:149-153.

32. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol. 1999;17:2506-2513.

33. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. // Journal of the American Statistical Association 1958 - N.53 - P.457-481.

34. Kelly WK, Curley T, Slovin S, et' al. Paclitaxel, estramustine phosphate and carboplatin in patients with advanced.prostate cancer. . J Clin Oncol 2001; 19:4453.

35. Kish J, Bukkapatnam R, et al.The treatment challenge of hormone-refractory prostate cancer.Cancer Care;2001;8(6):487-495.

36. Mayer FJ, Crawford ED. Update on combined androgen blockade for metastatic prostate cancer. Adv Urology. 1994;7:96.

37. McDonnel TJ, Navone NM, Troncoso P, et al. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol 157: 569-574, 1997.

38. Meyers FJ, Gumerlock PH, Chi SG, et al: Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer 15:25342539,1998.

39. Millikan RE. Chemotherapy of advanced prostatic carcinoma. Semin Oncol. 1999; 26:185-191.

40. Moor MJ, Osoba D, Murphy K, et al. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 1994;12(4):689-694.

41. Nishimura K, Nonomura N, Yasunaga Y, et al. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer. 2000;89:2570-2576.

42. Oh W. Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy. Cancer. 2000;88:3015-3021.

43. Osoba D, Tannock IF, Ernst SD, et al. Health related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999;17:1654-1663.

44. Petrylak DP, Macarthur RB, O'Connor J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol. 1999;17:958-967.

45. Petrylak DP. Molecular targets for the therapy of prostate cancer. ASCO. Educational Book: 574-577, 2000.

46. Piccart MJ, Klijn J, Paridaens R, et al. Steroids to reduce the severity and delay the onset of docetaxel induced fluid retention. Eur J Cancer 1995;31A: 575(Suppl 5,Abstr 347).

47. Pienta KJ, Lehr JE. Ingibition of prostate cancer growth by estramustine and etoposide: Evidence for interaction at the nuclear matrix. J Urol 149:16221625,1993.

48. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, and Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55: 4438-4445, 1995.

49. Sartor O, Weinberger M, Moore A, et al: Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology 1998;52:252-6.

50. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol. 1993; 11:1566-1572.

51. Scher HI, Mazumdar M, Kelly WK. Clinical trials in relapsed prostate cancer: defining the target. J Natl Cancer Inst. 1996;88: 1623-1634.

52. Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology. 1995;46:142-148.

53. Sinibaldi VJ, Carducci M, Moore-Cooper S, et al. A phase II study evaluating a one day course of estramustine phosphate and docetaxel in patients with hormone-refractory prostate cancer. Proc ASCO 1999; 18:322a.

54. Small EJ, Baron AD, Fippin L, et al. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol. 1997;157:1204-1207.

55. Small EJ, Reese DM, Vogelzang NJ. Hormone-refractory prostate cancer: an evolving standard of care. Semin Oncol. 1999; 26:61-67.

56. Small EJ, Srinivas S. The antiandrogen withdrawal syndrome: experience in a large cohort of unselected patients with advanced prostate cancer. Cancer. 1995;76:1428-1434.

57. Smith JA, Soloway MS, and Young M. Complications of advanced prostate cancer. Urology 54,6A: 8-14, 1999.

58. Stein CA. Mechanisms of action of taxanes in prostate cancer. Semin Oncol. 1999;26:3-7.

59. Tannock IF, Osoba D, Stockier MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756-1764.

60. Tonato M, Bracarda S. The role of chemotherapy in the treatment of prostatic carcinoma. Rays. 1993;18:87-93.

61. Vaishampain U, Parchment RE, Hussain M, et al. Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology 1999;54,6A: 22-29.

62. Vogelzang NJ, Crawford ED, Zietman A. Current clinical trial design issues in hormone-refractory prostate carcinoma. Consensus Panel. Cancer. 1998;82:2093-2101.

63. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993;71:1098-1109.

64. Yang CP, Shen HJ, Horowitz SB. Modulation of the function of p-glycoprotein by estramustine. J Natl Cancer Inst 86:3723-3724,1994.

Источник: http://www.dissercat.com/content/sravnenie-dvukh-r...


Аквариум сухоцветы на ногтях